Hyperekplexia: a treatable neurogenetic disease
- PMID: 12427512
- DOI: 10.1016/s0387-7604(02)00095-5
Hyperekplexia: a treatable neurogenetic disease
Abstract
Hyperekplexia is primarily an autosomal dominant disease characterized by exaggerated startle reflex and neonatal hypertonia. It can be associated with, if untreated, sudden infant death from apnea or aspiration pneumonia and serious injuries and loss of ambulation from frequent falls. Different mutations in the alpha1 subunit of inhibitory glycine receptor (GLRA1) gene have been identified in many affected families. The most common mutation is Arg271 reported in at least 12 independent families. These mutations uncouple the ligand binding and chloride channel function of inhibitory glycine receptor and result in increased excitability in pontomedullary reticular neurons and abnormal spinal reciprocal inhibition. Three mouse models from spontaneous mutations in GLRA1 and beta subunit of inhibitory glycine receptor (GLRB) genes and two transgenic mouse models are valuable for the study of the pathophysiology and the genotype-phenotype correlation of the disease. The disease caused by mutation in GLRB in mice supports the notion that human hyperekplexia with no detectable mutations in GLRA1 may harbor mutations in GLRB. Clonazepam, a gamma aminobutyric acid (GABA) receptor agonist, is highly effective and is the drug of choice. It enhances the GABA-gated chloride channel function and presumably compensates for the defective glycine-gated chloride channel in hyperekplexia. Recognition of the disease will lead to appropriate treatment and genetic counseling.
Copyright 2002 Elsevier Science B.V.
Similar articles
-
GLRB is the third major gene of effect in hyperekplexia.Hum Mol Genet. 2013 Mar 1;22(5):927-40. doi: 10.1093/hmg/dds498. Epub 2012 Nov 25. Hum Mol Genet. 2013. PMID: 23184146
-
[Hyperekplexia -- a treatable neuropediatric disease].Klin Padiatr. 2005 Jul-Aug;217(4):220-1. doi: 10.1055/s-2004-820286. Klin Padiatr. 2005. PMID: 16032547 German.
-
Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia.J Neurosci. 2010 Jul 14;30(28):9612-20. doi: 10.1523/JNEUROSCI.1763-10.2010. J Neurosci. 2010. PMID: 20631190 Free PMC article.
-
Hyperekplexia: abnormal startle response due to glycine receptor mutations.Br J Psychiatry. 1997 Feb;170:106-8. doi: 10.1192/bjp.170.2.106. Br J Psychiatry. 1997. PMID: 9093496 Review.
-
The genetics of hyperekplexia: more than startle!Trends Genet. 2008 Sep;24(9):439-47. doi: 10.1016/j.tig.2008.06.005. Epub 2008 Aug 15. Trends Genet. 2008. PMID: 18707791 Review.
Cited by
-
Hyperekplexia: Unveiling a Rare Neurological Condition With a Treatable Solution.Cureus. 2024 Jun 5;16(6):e61770. doi: 10.7759/cureus.61770. eCollection 2024 Jun. Cureus. 2024. PMID: 38975479 Free PMC article.
-
Propofol restores the function of "hyperekplexic" mutant glycine receptors in Xenopus oocytes and mice.J Neurosci. 2004 Mar 3;24(9):2322-7. doi: 10.1523/JNEUROSCI.4675-03.2004. J Neurosci. 2004. PMID: 14999083 Free PMC article.
-
Hyperekplexia: A Treatable Seizure Mimicker in Infants.Cureus. 2023 Apr 24;15(4):e38082. doi: 10.7759/cureus.38082. eCollection 2023 Apr. Cureus. 2023. PMID: 37252475 Free PMC article.
-
The synthetic cannabinoid dehydroxylcannabidiol restores the function of a major GABAA receptor isoform in a cell model of hyperekplexia.J Biol Chem. 2020 Jan 3;295(1):138-145. doi: 10.1074/jbc.RA119.011221. Epub 2019 Nov 22. J Biol Chem. 2020. PMID: 31757808 Free PMC article.
-
Allosteric modulators can restore function in an amino acid neurotransmitter receptor by slightly altering intra-molecular communication pathways.Br J Pharmacol. 2012 Apr;165(7):2110-2. doi: 10.1111/j.1476-5381.2011.01793.x. Br J Pharmacol. 2012. PMID: 22122331 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources